ArticleGene therapy2008
Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 93 citations in OpenAlex.
- Biomimetic phycocyanin lipid-based nanoparticles ameliorate placental dysfunction and restore angiogenic balance in a pre-eclampsia model.Journal of nanobiotechnology · 2026Article
- The human placenta and its role in reproductive outcomes revisited.Physiological reviews · 2025Review
- In utero therapy for spinal muscular atrophy: closer to clinical translation.Brain : a journal of neurology · 2025Review
- Article
- The role of placental hormones and metabolites in modulating uterine circulation in physiological and pathological pregnancies.Frontiers in endocrinology · 2025Review
- Efficiency of ultrasound-guided placental gene therapy in a rabbit IUGR model and effects on offspring development.Frontiers in veterinary science · 2025Article
- Placental Gene Therapy for Fetal Growth Restriction and Preeclampsia: Preclinical Studies and Prospects for Clinical Application.Journal of clinical medicine · 2024Review
- Maternal Uterine Artery Adenoviral Vascular Endothelial Growth Factor (Ad.VEGF-AReproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Extracellular vesicle-mediated targeting strategies for long-term health benefits in gestational diabetes.Clinical science (London, England : 1979) · 2023Review
- Article
- Ionizable Lipid Nanoparticles forJournal of the American Chemical Society · 2023Article
- Article
- Seasonal vascular plasticity in the mediobasal hypothalamus of the adult ewe.Histochemistry and cell biology · 2022Article
- Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review.Genes · 2021Review
- Uteroplacental Circulation in Normal Pregnancy and Preeclampsia: Functional Adaptation and Maladaptation.International journal of molecular sciences · 2021Review
- Luteolin-induced vasorelaxation in uterine arteries from normal pregnant rats.Pregnancy hypertension · 2021Article
- Comparison of Efficiency and Function of Vascular Endothelial Growth Factor Adenovirus Vectors in Endothelial Cells for Gene Therapy of Placental Insufficiency.Human gene therapy · 2020Article
- Placental Origins of Preeclampsia: Potential Therapeutic Targets.Current medical science · 2019Review
- Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact.Frontiers in endocrinology · 2019Review
- A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.Journal of the American Heart Association · 2017Article
Corrections and comments
- Erratum issuedNader, K A [corrected to Abi-Nader, K]
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Impaired materno-placental perfusion causes two important obstetric complications, fetal growth restriction and preeclampsia. This study investigated whether adenoviral vector-mediated overexpression of vascular endothelial growth factor (VEGF) in the uterine arteries (UtAs) increases uterine artery blood flow (UBF). First-generation adenovirus vectors (5 x 10(11) particles) containing the VEGF gene (Ad.VEGF-A or -D) or the beta-galactosidase reporter gene (Ad.lacZ) were injected into the UtAs of pregnant sheep (n=6) at 88-102 days of gestation (term=145 days). UBF was measured using Doppler sonography before, and 4-7 days after injection. Mean UBF increased significantly from 233+/-156 (s.d.) ml min(-1) to 753+/-415 ml min(-1) following Ad.VEGF-A injection (P=0.005, n=5); Ad.lacZ infection had no significant effect. Organ bath experiments on uterine arterial sections 4-7 days after injection showed that, compared with Ad.lacZ vessels, Ad.VEGF-A-transduced vessels had a reduced contractile response to phenylephrine (E max 148+/-10.9 vs E max 228.2+/-27.5, P<0.05) but increased relaxation with bradykinin (pD2 (-log EC50) values 9.11+/-0.01 vs 8.65+/-0.11, P<0.05). Injection of Ad.VEGF-A into the UtAs increases UBF by enhancing vasodilatation. This may provide the basis for therapy in pregnancies complicated by uteroplacental insufficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.